Trial Profile
A clinical study of Natalizumab treated multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 29 Jul 2018 New trial record
- 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology